For all press and media enquiries please contact mediarelations@chiesi.com
Chiesi Group announces mid-year turnover of €1,497 million; Substantial growth of each of Chiesi’s business areas; Europe remains the biggest market, followed by the US and China; Forecasted revenues of about €3 billion for 2023, with an additional solid growth expected in 2024. Parma (Italy), 3…
Alessandro Chiesi has held the post of Chief Commercial Officer since 2020, and succeeds Alberto Chiesi, who, together with his brother Paolo, led the Group to global expansion over the past five decades. Parma (Italy), July 7 th, 2023 – Chiesi announces the appointment of Alessandro Chiesi as Chair…
”Rare Land” is a movie by Eftimiz Hatzis, which gives the audience a front-row seat to understand the difficult experience of a family facing a rare disease, such as alpha-mannosidosis. Challenges in the early diagnosis of rare and ultra-rare diseases and opportunities to increasingly support…
- Following the recent European Commission Authorization, FDA approves PRX-102 for the treatment of Fabry disease - PARMA, BOSTON and CARMIEL, Israel, May 10, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people…
- PEGylated enzyme replacement therapy designed to provide a long half-life - PARMA, Italy, BOSTON and CARMIEL, Israel, May 5 th, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases,…
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland and Boston MA, April 12, 2023 – Chiesi Farmaceutici S.p.A. (“Chiesi”), an international, research-focused…
Turnover at €2 billion 749 million, with growth of 13.6% over 2021; The European market remains at the center, with significant international development; The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare diseases) 12% and Care…
International Call for ideas for the regeneration of the Chiesi pharmaceutical group's historic industrial site at Via Palermo, Parma March 1 st – April 30 th, 2023 Starting today, Wednesday 1 March, Restore to Impact - The next healthcare landmark for innovation and future-oriented competences, an…
Giuseppe Accogli is a successful Executive Leader with 25 years of international experience in the Med-tech sector of reputed and complex companies such as Tyco Healthcare (Covidien), Baxter and Medtronic. “As CEO, I strive to enable our leaders, people and partners to achieve even greater success…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
